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ABSTRACT The genome of inﬂuenza virus (viral RNA [vRNA]) is associated with the
nucleoprotein (NP) and viral RNA-dependent RNA polymerases and forms helical vi-
ral ribonucleoprotein (vRNP) complexes. The NP-vRNA complex is the biologically ac-
tive template for RNA synthesis by the viral polymerase. Previously, we identiﬁed hu-
man pre-mRNA processing factor 18 (Prp18) as a stimulatory factor for viral RNA
synthesis using a Saccharomyces cerevisiae replicon system and a single-gene dele-
tion library of Saccharomyces cerevisiae (T. Naito, Y. Kiyasu, K. Sugiyama, A. Kimura, R.
Nakano, A. Matsukage, and K. Nagata, Proc Natl Acad Sci USA, 104:18235–18240,
2007, https://doi.org/10.1073/pnas.0705856104). In infected Prp18 knockdown (KD)
cells, the synthesis of vRNA, cRNA, and viral mRNAs was reduced. Prp18 was found
to stimulate in vitro viral RNA synthesis through its interaction with NP. Analyses us-
ing in vitro RNA synthesis reactions revealed that Prp18 dissociates newly synthe-
sized RNA from the template after the early elongation step to stimulate the elonga-
tion reaction. We found that Prp18 functions as a chaperone for NP to facilitate the
formation of NP-RNA complexes. Based on these results, it is suggested that Prp18
accelerates inﬂuenza virus RNA synthesis as an NP chaperone for the processive
elongation reaction.
IMPORTANCE Templates for viral RNA synthesis of negative-stranded RNA viruses
are not naked RNA but rather RNA encapsidated by viral nucleocapsid proteins
forming vRNP complexes. However, viral basic proteins tend to aggregate under
physiological ionic strength without chaperones. We identiﬁed the pre-mRNA pro-
cessing factor Prp18 as a stimulatory factor for inﬂuenza virus RNA synthesis. We
found that one of the targets of Prp18 is NP. Prp18 facilitates the elongation reac-
tion of viral polymerases by preventing the deleterious annealing of newly synthe-
sized RNA to the template. Prp18 functions as a chaperone for NP to stimulate the
formation of NP-RNA complexes. Based on these results, we propose that Prp18 may
be required to maintain the structural integrity of vRNP for processive template
reading.
KEYWORDS host factor, protein chaperones, ribonucleoprotein, viral RNA synthesis
The genome of inﬂuenza A virus is composed of eight-segmented and single-stranded RNAs of negative polarity and exists as a ribonucleoprotein (RNP) (termed
viral RNP [vRNP]) complex with nucleoprotein (NP) and viral RNA-dependent RNA
polymerases (RdR Pol) consisting of three subunits, PB1, PB2, and PA. NP binds to the
virus genome (viral RNA [vRNA]) through a phosphate backbone without sequence
speciﬁcity (1, 2). vRNP forms a helical structure, and RdR Pol is located at the open end
of the RNP hairpin structure formed by the interaction between the 5= and 3= ends of
Received 13 July 2016 Accepted 13
November 2016
Accepted manuscript posted online 16
November 2016
CitationMinakuchi M, Sugiyama K, Kato Y,
Naito T, Okuwaki M, Kawaguchi A, Nagata K.
2017. Pre-mRNA processing factor Prp18 is a
stimulatory factor of inﬂuenza virus RNA
synthesis and possesses nucleoprotein
chaperone activity. J Virol 91:e01398-16.
https://doi.org/10.1128/JVI.01398-16.
Editor Adolfo García-Sastre, Icahn School of
Medicine at Mount Sinai
Copyright © 2017 American Society for
Microbiology. All Rights Reserved.
Address correspondence to K. Nagata,
knagata@md.tsukuba.ac.jp.
* Present address: Y. Kato, Department of
Applied Chemistry and Biotechnology,
Graduate School of Natural Science and
Technology, Okayama University, Kita-ku,
Okayama, Japan; T. Naito, Department of
Microbiology, Kawasaki Medical School,
Kurashiki, Okayama, Japan.
M.M. and K.S. contributed equally to this article.
GENOME REPLICATION AND REGULATION
OF VIRAL GENE EXPRESSION
crossm
February 2017 Volume 91 Issue 3 e01398-16 jvi.asm.org 1Journal of Virology
 o
n
 January 18, 2017 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
vRNA (3–6). The vRNP complex is essential for the transcription and replication of the
inﬂuenza virus genome as an enzyme-template complex, and some host factors have
been found to be involved in these reactions (reviewed in reference 7). Transcription
from vRNA initiates with a capped oligoribonucleotide derived from cellular pre-mRNAs
as a primer, whereas viral genome replication is primer independent and host factor
dependent and generates full-length vRNA through cRNA synthesized from vRNA (7).
It has been postulated that NP encapsidates de novo RNA and regulates the RdR Pol
function through the interaction with PB1 and PB2 (8–12). It has been reported that
encapsidation is coupled with replication processes (11) and initiated by successive
targeting of the exogenous NP monomer to RdR Pol, which is distinct from the
replicative polymerase and binds to the 5= end of nascent RNA (13), and additional NPs
are then subsequently recruited by NP-NP oligomerization (14). Encapsidation is also
important for the stabilization of nascent cRNA to protect the virus from degradation
by cellular nucleases (15).
It is known that the maximal level of replication and transcription of the inﬂuenza
virus genome requires not only viral components associated with virions but also some
host factors present in infected cells (11, 16–22). We reconstituted a cell-free viral RNA
synthesis system with virion-associated vRNP and nuclear extracts prepared from
uninfected HeLa cells (19, 23). By reconstitution and dissection of the cell-free system,
we have identiﬁed RAF-1/Hsp90, IREF-1/MCM, and RAF-2p48/UAP56/BAT1 as host
factors that stimulate viral RNA synthesis (24–26). In addition, we also established an
inﬂuenza virus replicon system in Saccharomyces cerevisiae and identiﬁed Tat-SF1 as a
host factor using a yeast single-gene deletion library (27). RAF-1/Hsp90 regulates the
assembly of the viral RNA polymerase complex and is also involved in its stabilization
during transfer between templates (28). IREF-1/MCM stabilizes replicating polymerase
complexes by stabilizing the interaction between nascent cRNA and PA (24). RAF-2p48
and Tat-SF1 facilitate viral RNA synthesis as NP chaperones (11, 26, 27).
Here, we have identiﬁed another host factor, Prp18, as a stimulatory factor for
inﬂuenza virus RNA synthesis using the yeast single-gene deletion library screening
system (27). Prp18 is associated with U5 snRNP and plays an important role in catalytic
step II in pre-mRNA splicing (29–31) to stabilize the interaction of the ends of exons
with loop 1 of U5 snRNA (32). We found that Prp18 stimulates the RNA synthesis of the
inﬂuenza virus genome and interacts with NP directly in vitro and in vivo. Biochemical
analyses indicated that Prp18 is involved in the formation of NP-RNA complexes. Based
on these results, we propose that Prp18 is one of the NP chaperones.
RESULTS
Prp18 stimulates viral RNA synthesis in vitro. Previously, we established an
inﬂuenza virus replicon system in yeast and a screening system using a single-gene
deletion yeast library, both of which enabled us to identify candidate host factors
involved in inﬂuenza virus RNA synthesis (27). Using this system, we have identiﬁed
Prp18 as one of the candidate host factors. The RNA synthesis level was decreased by
40% in Prp18 deletion yeast cells compared to that in wild-type cells (27). Yeast Prp18
shares 39% identity with human Prp18. This factor is associated with U5 snRNP and
functions in catalytic step II in pre-mRNA splicing as a splicing factor (29–32). Prp18
contains a splicing factor motif (SFM) in the N-terminal region, which is a Prp4-like motif
with two weakly folded helices, and a Prp18 motif in the C-terminal region (33). The
C-terminal Prp18 domain associates with U5 snRNP and the Slu7 protein during splicing
(29, 34). The N-terminal Prp18 SFM domain interacts with the basic protein hCypH (35).
To conﬁrm that Prp18 has stimulatory activity for viral RNA synthesis, we carried out
cell-free inﬂuenza virus RNA synthesis assays. We puriﬁed recombinant glutathione
S-transferase (GST)-Prp18 and GST proteins using an Escherichia coli expression system
(Fig. 1A). vRNP, as an enzyme source, was incubated with an exogenously added
53-nucleotide (nt)-long model vRNA (termed v53) in the presence of GST-Prp18 or GST,
and synthesized RNAs were analyzed by electrophoresis through a denaturing gel.
GST-Prp18 stimulated viral RNA synthesis from exogenous v53 as well as endogenous
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RNAs in a Prp18 dose-dependent manner (Fig. 1B), suggesting that Prp18 enhances the
viral RNA synthesis activity, possibly by interacting with RdR Pol, NP, and/or the virus
genome.
Effect of Prp18 knockdown on inﬂuenza virus-infected cells. Next, we examined
the function of Prp18 in inﬂuenza virus-infected cells using small interfering RNA
(siRNA) against Prp18 (siPrp18). The amount of Prp18 was reduced to 10% in cells
transfected with Prp18 siRNA compared to that in control siRNA-transfected cells (Fig.
2A). The transfection of Prp18 siRNA showed negligible cytotoxicity compared to that
of control siRNA (Fig. 2B). The virus titer in Prp18 knockdown (KD) cells decreased to
10% of that in control cells (Fig. 2C). Although the amount of NP was saturated at 7
h postinfection (hpi), the protein synthesis levels of PB1, PB2, PA, and NP were reduced
by40% in siPrp18-transfected cells compared with those in control siRNA-transfected
cells (Fig. 2D) (the signal intensities were measured by using Image J software). Based
on these results, it is possible that Prp18 is involved in viral protein synthesis and/or
viral RNA synthesis. Thus, we investigated the levels of vRNA, cRNA, and viral mRNA in
infected cells by quantitative reverse transcription-PCR (RT-PCR). The levels of segment
3, 5, and 7 vRNAs, cRNAs, and their mRNAs were decreased in Prp18 KD cells (Fig. 2E).
Because Prp18 is one of the splicing factors, it is possible that Prp18 KD may have some
effects on the splicing of viral pre-mRNAs and therefore on viral RNA synthesis. To
examine this, we determined the ratio of the level ofM1mRNA to that ofM2mRNA, the
latter of which is generated from M1 mRNA by splicing. In Prp18 KD cells, the amounts
of both M1 and M2 mRNAs were reduced by 40% compared to those in control cells,
but the ratio of the M2 mRNA level to the M1 mRNA level was decreased by Prp18 KD
only slightly (Fig. 2F), indicating that Prp18 KD has little effect on splicing under the
conditions employed here.
Prp18 is involved in primary transcription of incoming vRNP. Because the newly
synthesized viral genome served as a template for viral mRNA synthesis, we investi-
gated the effect of Prp18 on primary transcription from incoming vRNP in Prp18 KD
cells in the presence of cycloheximide (CHX), which is a potent protein synthesis
inhibitor and inhibits the replication process (15, 36). The level of NPmRNA in Prp18 KD
cells was reduced to30% of that in control cells in the presence of CHX (Fig. 3A, lanes
2 and 4). Next, we carried out complementation experiments for siRNA-transfected cells
with a plasmid encoding siRNA-resistant Prp18 (rPrp18)-Myc containing a silent muta-
tion within the siRNA target sequence. The NPmRNA synthesis level was rescued by the
expression of rPrp18-Myc (Fig. 3A, compare lane 5 with lane 4). We also conﬁrmed that
the expression level of rPrp18-Myc in Prp18 KD cells was similar to that of the
FIG 1 Stimulation of viral RNA synthesis by Prp18 in vitro. (A) Puriﬁed GST and GST-Prp18 were separated
by SDS-PAGE and visualized by Coomassie brilliant blue staining. (B) Effect of Prp18 on cell-free RNA
synthesis. Cell-free RNA synthesis was carried out by using vRNP (3 ng of NP equivalents) as an enzyme
source and v53 in the presence of increasing amounts of GST (lane 2, 30 ng; lane 3, 100 ng; lane 4, 300
ng) and GST-Prp18 (lane 5, 30 ng; lane 6, 100 ng; lane 7, 300 ng). RNA products from endogenous viral
RNA present in vRNP are shown at the top of a 10% PAGE gel in the presence of 8 M urea, and RNA
products from the 53-mer model vRNA are indicated by an arrowhead.
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endogenous Prp18 protein in control siRNA-treated cells (Fig. 3B, lanes 2 and 5). From
these results, we concluded that Prp18 is a positive factor for viral mRNA synthesis in
infected cells.
The interaction between NP and Prp18 is responsible for stimulation of viral
RNA synthesis by Prp18. To examine which viral factor(s) interacts with Prp18, we
FIG 2 Effect of Prp18 knockdown on viral RNA synthesis. (A) HeLa cells were transfected with control siRNA or
siPrp18. At 72 h posttransfection, cell lysates were subjected to Western blotting using anti-Prp18 and anti--actin
antibodies. (B) Seventy-two hours after transfection of siRNA, the viability of control and Prp18 KD cells was
determined by trypan blue staining. The averages and standard deviations determined from three independent
experiments are shown. (C) Seventy-two hours after transfection of siRNA, control and Prp18 KD cells were infected
with inﬂuenza virus at an MOI of 0.01. The culture supernatants collected at 12, 24, 36, 48, 60, and 72 hpi were
subjected to plaque assays to examine the production of infectious virions. The average titers and standard
deviations determined from three independent experiments are shown. (D) Seventy-two hours after transfection
of siRNA, control (lanes 1, 3, 5, and 7) and Prp18 KD (lanes 2, 4, 6, and 8) cells were infected with inﬂuenza virus
at an MOI of 3. At 3, 5, and 7 hpi, the cell lysates were subjected to Western blotting with anti-PB1, anti-PB2, anti-PA,
anti-NP, and anti--actin antibodies. (E) Control and Prp18 KD cells were infected with inﬂuenza virus at an MOI of
3 and incubated for 3, 5, and 7 h. Total RNA was prepared from cells, and quantitative RT-PCR was carried out with
primer sets speciﬁc for segment 3 vRNA, segment 3 cRNA, segment 3 mRNA, segment 5 vRNA, segment 5 cRNA,
segment 5 mRNA, segment 7 vRNA, segment 7 cRNA, and segment 7 mRNA. The results were normalized to the
level of 18S rRNA. The averages and standard deviations determined in three independent experiments are shown.
The level of signiﬁcance was determined by Student’s t test (*, P  0.01; **, P  0.05; ***, P  0.5). (F) HeLa cells
were transfected with control siRNA or siPrp18. At 72 h posttransfection, cells were infected with inﬂuenza virus
at an MOI of 3 and incubated for 5 h. Total RNA was prepared from cells, and quantitative RT-PCR was carried out
with primer sets speciﬁc for M1 mRNA and M2 mRNA. The results were normalized to the level of 18S rRNA. The
ratio of the amount of M2 mRNA to that of M1 mRNA was also determined in three independent experiments, with
standard deviations. The level of signiﬁcance was determined by Student’s t test (*, P  0.01; **, P  0.05).
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carried out immunoprecipitation assays using cell lysates prepared from infected cells
expressing Prp18-Myc. As shown in Fig. 4A, Prp18-Myc interacted with both NP and RdR
Pol. However, it was not clear whether Prp18 binds to them directly or through some
component of vRNP. We then investigated a target of Prp18 using micrococcal
nuclease-treated vRNP (mnRNP) (Fig. 4B). Micrococcal nuclease digests viral RNA and
produces viral proteins free of RNA. GST-Prp18 interacted with NP and RdR Pol in the
absence of viral RNA. It was assumed that Prp18 binds to NP and RdR Pol independently
or through NP or RdR Pol, both of which interact with each other (9). Therefore, to
examine the interaction between NP and Prp18, we carried out GST pulldown assays
with recombinant His-tagged NP (His-NP) and GST-Prp18. Figure 4C shows that NP
binds GST-Prp18 in a dose-dependent manner.
To identify the viral protein responsible for the stimulatory activity of viral RNA
synthesis by Prp18, we carried out GST pulldown assays using lysates prepared from
infected cells expressing GST-fused deletion mutants of Prp18. We constructed
FIG 3 Effect of Prp18 on primary transcription. (A) HeLa cells were transfected with control siRNA or
siPrp18. At 48 h posttransfection, cells were transfected with the pCAGGS-rPrp18-Myc (containing a silent
mutation within the siRNA target sequence) and pCAGGS-empty plasmids. After 24 h posttransfection,
cells were superinfected with inﬂuenza virus at an MOI of 3 and incubated for 4 h in the presence of
cycloheximide (CHX). Total RNAs were subjected to quantitative RT-PCR with a primer set speciﬁc for
segment 5 mRNA. The results are normalized to the level of 18S rRNA. The averages and standard
deviations determined from three independent experiments are shown. The level of signiﬁcance was
determined by Student’s t test (*, P  0.01). (B) Western blotting was conducted by using infected cells
prepared as described above for panel A. Cell lysates were loaded onto a 10% SDS-PAGE gel and
subjected to Western blotting with anti-Prp18 antibody.
FIG 4 Prp18 interacts with NP and viral polymerase in vivo and in vitro. (A) HEK293T cells were transfected with either pCAGGS or
pCAGGS-Prp18-Myc. At 48 h posttransfection, these cells were infected with inﬂuenza virus at an MOI of 3 and incubated for 6 h. Cell
lysates were prepared and incubated with either control IgG-conjugated (lanes 3 and 5) or anti-Myc antibody-conjugated agarose (lanes
4 and 6). Pulldown products were visualized by immunoblotting using anti-PB1, anti-PB2, anti-PA, anti-NP, and anti-Myc antibodies. (B)
GST pulldown assays were carried out by using puriﬁed GST-Prp18 (lanes 5 to 7) and either vRNP (lanes 1, 3, and 6) or mnRNP (lanes 2,
4, and 7). Western blot analyses were carried out with anti-GST, anti-PB1, anti-PB2, anti-PA, and anti-NP antibodies. (C) GST pulldown
assays were conducted by using puriﬁed GST (lane 1, 0.6 pmol), GST-Prp18 (lane 2, 0.6 pmol; lane 3, 2 pmol; lane 4, 6 pmol), and His-NP
(lanes 1 to 4, 1.25 pmol). Western blotting was carried out with anti-His and anti-GST antibodies.
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C-terminally truncated mutants of Prp18 (Prp18C1, Prp18C2, and Prp18Δ71) (Fig. 5A).
Similarly to the wild type, these mutant proteins were localized mainly in the nucleus
(Fig. 5B). We found that Prp18C2 hardly interacts with RdR Pol and NP in infected cells
(Fig. 5C, lane 4). Prp18C1 and Prp18Δ71 interacted with NP but not RdR Pol, although
FIG 5 Prp18 stimulates viral RNA synthesis through interaction with NP. (A) Schematic diagram of Prp18 deletion mutants. a.a, amino
acids. (B) Intracellular localization of GST-tagged Prp18 deletion mutants. HeLa cells were transfected with plasmids expressing GST-Prp18,
GST-Prp18C1, GST-Prp18C2, and GST-Prp18Δ71. At 24 h posttransfection, cells were subjected to indirect-immunoﬂuorescence assays with
anti-GST antibody. DAPI, 4=,6-diamidino-2-phenylindole. (C) GST pulldown assays of GST-Prp18 deletion mutants. HEK293T cells were
transfected with plasmids expressing GST-Prp18, GST-Prp18C1, GST-Prp18C2, and GST-Prp18Δ71. At 24 h posttransfection, cells were
infected with inﬂuenza virus at an MOI of 3. At 6 hpi, cell lysates were prepared and subjected to GST pulldown assays. Coprecipitated
proteins were analyzed by Western blotting with anti-PB1, anti-PB2, anti-PA, anti-NP, and anti-GST antibodies. nls, nuclear localization
signal. (D) HEK293T cells were transfected with plasmids expressing NP and either GST-Prp18, GST-Prp18C1, GST-Prp18C2, or GST-
Prp18Δ71. At 24 h posttransfection, cell lysates were prepared and subjected to a GST pulldown assay. Coprecipitated proteins were
analyzed by Western blotting with anti-NP and anti-GST antibodies. (E) Puriﬁed recombinant GST, GST-Prp18, GST-Prp18C2, and
GST-Prp18Δ71 were separated by 10% SDS-PAGE and visualized by staining with Coomassie brilliant blue. (F) Effect of Prp18 on cell-free
RNA synthesis. Cell-free RNA synthesis was carried out with 0.3 pmol (lanes 1, 4, 7, and 10), 1 pmol (lanes 2, 5, 8, and 11), and 3 pmol (lanes
3, 6, 9, and 12) of GST (lanes 1 to 3), GST-Prp18C2 (lanes 4 to 6), GST-Prp18WT (lanes 7 to 9), and GST-Prp18Δ71 (lanes 10 to 12), as
described in the legend of Fig. 1.
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the interaction level of these mutants was lower than that of wild-type Prp18 (Prp18WT)
(Fig. 5C, lanes 3 and 5). To conﬁrm the interaction between NP and Prp18 mutants, we
performed GST pulldown assays with lysates prepared from cells expressing NP and
each Prp18 mutant. It was revealed that Prp18C1 and Prp18Δ71 interacted with NP in
the absence of RdR Pol (Fig. 5D). Thus, we carried out cell-free viral RNA synthesis assays
using GST-Prp18C2 and GST-Prp18Δ71 (Fig. 5E and F). These assays showed that
GST-Prp18WT and GST-Prp18Δ71, but not Prp18C2, stimulated viral RNA synthesis from
exogenous v53 as well as endogenous viral RNAs in a Prp18 dose-dependent manner,
suggesting that Prp18 activates viral RNA synthesis through the interaction between
Prp18 and NP.
Prp18 dissociates newly synthesized RNA from the template and stimulates
elongation after the early elongation step. To clarify the role of Prp18 in viral RNA
synthesis, we carried out cell-free viral RNA synthesis assays by incubating cells for 0, 1,
2, and 4 min to examine the effect of Prp18 on initiation and elongation reactions.
Approximately 60-, 200-, and 300-nt-long viral RNAs were mainly synthesized by 1-,
2-, and 4-min incubations, respectively (Fig. 6A). We found that the amount of shorter
newly synthesized RNAs (200 nt) was not changed by the addition of Prp18 (Fig. 6A,
lanes 3, 4, 7, and 8). In contrast, the amount of longer RNAs (300 nt) was increased
in the presence of Prp18 (Fig. 6A, compare lane 9 with lane 5), suggesting that Prp18
stimulates the elongation step but not the initiation step. To conﬁrm the effect of Prp18
on the initiation reaction, we performed a limited elongation reaction in which UTP is
omitted from the reaction mixture and, thus, RdR Pol pauses at the ﬁrst adenine residue
on the template. The expected lengths of the limited elongation products are 12 nt for
segments 1, 3, and 7; 13 nt for segments 5 and 8; 14 nt for segment 6; 18 nt for segment
4; and 19 nt for segment 2. As expected, we detected comparable amounts of each RNA
product in the absence or presence of Prp18 (Fig. 6B). Thus, it is likely that Prp18 is
required for a step(s) after the early elongation process, in which short RNAs are
synthesized.
It has been speculated that without newly synthesized NP and a molecular chap-
erone such as RAF-2p48/UAP56, the nascent RNA chains hybridize with template
strands (11), and this hybridization may result in the premature termination of RNA
synthesis. Next, in order to examine the amount of newly synthesized RNA hybridizing
to the template in the absence or presence of Prp18, we digested the nascent RNA
chains with RNase T2, which is a single-stranded RNA-speciﬁc nuclease (Fig. 6C). At 4
FIG 6 Prp18 stimulates viral RNA synthesis after the early elongation process. (A) Time course of cell-free viral RNA synthesis. Cell-free viral
RNA synthesis was carried out in the presence of either GST (lanes 2 to 5) or GST-Prp18 (lanes 6 to 9), as described in the legend of Fig.
1. After 0-, 1-, 2-, and 4-min incubations, samples were collected and analyzed by using 8 M urea–10% PAGE gels. (B) Limited elongation
assays were carried out in the presence of either GST (lanes 1 to 3) or GST-Prp18 (lanes 4 to 6) in the absence of UTP. Samples were
analyzed by using 8 M urea–15% PAGE gels. (C) RNase T2 digestion assay. Cell-free RNA synthesis was carried out in the presence of either
GST (lanes 1 to 3) or GST-Prp18 (lanes 4 to 6). The newly synthesized RNAs were digested with 6.6 U (lanes 2 and 5) and 20 U (lanes 3
and 6) of RNase T2. The digested RNAs were analyzed by using 8 M urea–4% PAGE gels. (D) The signal intensities of each lane were
measured by using ImageJ software. Averages and standard deviations determined from three independent experiments are shown.
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min postincubation, the reaction of cell-free viral RNA synthesis was stopped by the
addition of 50 mM EDTA, and the reaction mixtures were subjected to RNase T2
digestion. In the absence of GST-Prp18, newly synthesized viral RNAs were resistant to
RNase T2 digestion, suggesting that the nascent chains hybridize with template strands
(Fig. 6C and D, lanes 1 to 3). In contrast, the Prp18-stimulated longer RNA products were
highly sensitive to RNase T2 digestion (Fig. 6C and D, lanes 4 to 6). From these results,
it is possible that Prp18 dissociates the newly synthesized RNA from the template after
the early elongation step and then stimulates the elongation reaction of viral RNA
synthesis.
Prp18 facilitates the formation of NP-RNA complexes. Based on the structural
and functional features of Prp18 described above, we focused our study on the Prp18
function related to NP. We hypothesized that Prp18 may function as an NP chaperone
in viral RNA synthesis. First, we performed gel shift assays to examine whether Prp18
plays a role in the formation of NP-RNA complexes (Fig. 7). His-NP and GST-Prp18
expressed in E. coli were puriﬁed (Fig. 7A). Gel shift assays with 5=-32P-labeled v53
showed that NP-RNA complexes are formed in an NP dose-dependent manner (Fig. 7B).
The complex retained at the gel top, a quite large complex, includes the aggregation
of NP and 5=-32P-labeled v53. To examine whether Prp18 facilitates the formation of
NP-RNA complexes, His-NP and GST-Prp18 were mixed and incubated at 30°C for 30
min. Each sample was then mixed with v53 and incubated at 30°C for 30 min. In the
presence of a limited amount of NP, NP-RNA complex formation was increased by
Prp18 (Fig. 7C and D). It is worth noting that Prp18 does not bind to v53 (Fig. 7C, lane
8). Taken together, these results suggest that Prp18 has the NP chaperone activity that
facilitates the formation of NP-RNA complexes.
DISCUSSION
We have identiﬁed Prp18 as a stimulatory factor for viral RNA synthesis activity in
vitro and in vivo. Prp18 dissociates the newly synthesized RNA from the template after
the early elongation step and thus stimulates the elongation reaction of viral RNA
synthesis (Fig. 6). We also demonstrated the possibility that Prp18 is a molecular
chaperone for NP-RNA complex formation, as are RAF-2p48/UAP56 (26) and Tat-SF1
(27) (Fig. 7).
Prp18 and the previously identiﬁed NP chaperones RAF-2p48/UAP56 and Tat-SF1
are related to the splicing reaction (26, 27). It has been reported that spliceosomes are
partially destroyed by the inﬂuenza virus NS1 protein (26, 37). The release of these
splicing factors from spliceosomes is useful for recruiting these factors for viral RNA
transcription and replication in the nucleus. The inﬂuenza virus RdR Pol recognizes host
FIG 7 Prp18 facilitates NP-RNA complex formation in vitro. (A) Puriﬁcation of the GST-Prp18 and His-NP proteins. Details are described in
Materials and Methods. Puriﬁed proteins were loaded onto a 10% SDS-PAGE gel and visualized by Coomassie brilliant blue staining. (B)
Gel shift assays were carried out with 5=-32P-labeled v53 and His-NP. NP-RNA complexes were separated on a 0.6% agarose gel and
detected by autoradiography. (C and D) His-NP (lanes 1 to 7, 12.5 fmol) and increasing amounts of GST-Prp18 (lane 2, 0.013 pmol; lane
3, 0.04 pmol; lane 4, 0.13 pmol; lane 5, 0.4 pmol; lane 6, 1.3 pmol; lanes 7 and 8, 4 pmol) were incubated at 30°C for 30 min. After further
incubation with 5=-32P-labeled v53, samples were separated on a nondenaturing gel and subjected to autoradiography. In panel D, the
band intensities were quantitatively measured by using ImageJ software, and the averages and standard deviations determined from
three independent experiments are shown. The level of signiﬁcance was determined by Student’s t test (*, P  0.01; **, P  0.05). AU,
arbitrary units.
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pre-mRNAs containing the cap structure for the preparation of primers for viral tran-
scription, and viral transcription was found to be dependent on transcriptionally
functional host RNA polymerase II complexes (38–40), which are also associated with
splicing factors. Splicing occurs cotranscriptionally (41), so vRNP could be associated
with these complexes.
It has been reported that RAF-2p48/UAP56 stimulates the encapsidation of nascent
RNA chains in concert with viral RNA synthesis (11). The coreplicational encapsidation
of nascent chains by NP prevents the premature termination of viral RNA synthesis. It
is worth noting that RAF-2p48/UAP56 stimulates viral RNA synthesis from a naked RNA
template by recruiting NP to RNA but not from vRNP (26). Here, we showed that Prp18
dissociates newly synthesized RNA from the template after the early elongation step
and stimulates the elongation reaction. In contrast to RAF-2p48/UAP56, Prp18 en-
hances viral RNA synthesis from vRNP, suggesting that Prp18 functions as a chaperone
of NP on the virus genome. The binding of NP to the virus genome is required to form
the vRNP template for an efﬁcient elongation reaction by RdR Pol (8–12). A recent
structural model of RdR Pol of a segmented negative-strand RNA virus led to the
proposal that the disruption of the vRNP structure during template reading is restricted
around the active center due to the proximity of the entry and exit channels of
template (42). Based on these ﬁndings, it is possible that Prp18 functions as a molecular
chaperone for NP around the active center of RdR Pol to maintain the structural
integrity of vRNP for processive template reading. It has been reported that PB2 has NP
and PB1 binding sites, and the binding of NP to PB2 could be outcompeted by PB1 (43).
It has also been hypothesized that the interaction between NP and RdR Pol might play
a role in switching the activity of RdR Pol from transcription to replication (8, 10, 15, 44,
45). To further understand the effect of NP on viral RNA synthesis, biochemical and
structural analyses focusing on RdR Pol during template reading are required.
The interaction between NP and RdR Pol is thought to be involved in the targeting
of exogenous NP to newly synthesized virus genomes (13). We found that Prp18
depletion reduces the viral polymerase activity (Fig. 2E), but the viral titer was de-
creased more signiﬁcantly by Prp18 KD (Fig. 2C). Prp18 was also shown to interact with
NP and RdR Pol (Fig. 4). Thus, it is possible that Prp18 is required for postreplicational
processes through vRNP encapsidation in addition to the stimulation of viral polymer-
ase activity.
MATERIALS AND METHODS
Cells, virus infection, and transfection. Monolayer cultures of HeLa cells and MDCK cells were
maintained at 37°C in minimal essential medium (MEM) containing 10% fatal bovine serum (FBS) (Gibco).
HeLa cells were infected with inﬂuenza virus A/Puerto Rico/8/34 at a multiplicity of infection (MOI) of 3.
After virus adsorption at 37°C for 1 h, cells were washed twice with serum-free MEM and incubated at
37°C for 3 to 7 h with MEM containing 10% FBS. Transfection was carried out by using Genejuice
transfection reagent (Merck Millipore) according to the manufacturer’s instructions.
Vector construction. Full-length human Prp18 cDNA was ampliﬁed by PCR using cDNA prepared
from total RNA of HeLa cells as the template, using primers 5=-CCGAATTCGCCGCCACCATGGACTACAA
GGATGACGACGACAAGGGAATGGACATTCTGAAATCAGAGATCC-3= and 5=-GGGAATTCTCACAGTGCATTGT
ACTCCACAC-3=. The PCR fragment was phosphorylated by using T4 polynucleotide kinase (Toyobo)
and cloned into SmaI-digested pGEX-6p-1 (pGEX-Prp18). For the construction of the siRNA-resistant
Prp18 expression vector, synonymous mutations were introduced into the siRNA-targeting sequence
by PCR using a primer with site-directed mutations, 5=-TCCTCCTCTTTGGGTTGGATTTTATACCCGCAT
CTTTCAAAATA-3=, and primers described above.
Antibodies. Rabbit anti-PB1, anti-PB2, anti-PA, and anti-NP antibodies were prepared as previously
described (28, 46). Mouse polyclonal antibodies against human Prp18 (Sigma-Aldrich), the His tag
(Sigma-Aldrich), the GST tag (Nacalai), and the Myc tag (Nacalai) were purchased.
Preparation of recombinant proteins. GST-Prp18 was puriﬁed by using glutathione-Sepharose 4B
beads (GE health care) according to the manufacturer’s protocols. His-tagged NP (His-NP) was prepared
as previously described (11). To reduce contamination by bacterial RNA, recombinant NP was washed
with 1 M NaCl. Puriﬁed NP with a ratio of the absorbance at 260 nm to that at 280 nm of between 0.57
and 0.59 was used for this study.
Cell-free inﬂuenza virus RNA synthesis. Procedures for the puriﬁcation of virions and the isolation
of vRNP complexes were described previously (19, 23, 26). Cell-free inﬂuenza virus RNA synthesis was
carried out at 30°C for 1 h in a ﬁnal volume of 20 l containing 50 mM HEPES-NaOH (pH 8.0); 3 mMMgCl2;
1.5 mM dithiothreitol; 50 mM KCl; 500 M each ATP, CTP, and UTP; 25 M GTP; 5 Ci of [-32P]GTP (3,000
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Ci/mmol); 4 U of an RNase inhibitor; 100 M ApG dinucleotide; 30 nM 53-nt-long model vRNA template
(5=-AGUAGAAACAAGGGUGUUUUUUCAUAUCAUUUAAACUUCACCCUGCUUUUGCU-3=), and vRNP as an
enzyme source. RNA products were puriﬁed, separated on 10% PAGE gels containing 8 M urea, and
detected by autoradiography.
Immunoprecipitation assay. Cells were suspended in lysis buffer containing 20 mM Tris-HCl (pH
8.0), 100 mM NaCl, 30 mM KCl, 1 mM EDTA, and 0.1% NP-40. After sonication with a BioRuptor (Cosmo
Bio), the cell lysates were centrifuged at 13,000  g at 4°C for 5 min. The supernatant fractions were
incubated with anti-Myc antibody-conjugated agarose at 4°C for 1 h. After washing with lysis buffer,
immunoprecipitated proteins were analyzed by immunoblotting using anti-PB1, anti-PB2, anti-PA,
anti-NP, and anti-Myc antibodies.
Gel shift assay. His-NP and Prp18 were incubated at 30°C for 30 min in a buffer containing 50 mM
HEPES-NaOH (pH 8.0), 20 mM KCl, 1.2 mM MgCl2, 0.6 mM dithiothreitol, 0.1% NP-40, 5=-32P-labeled
53-nt-long model vRNA, and 4 U of the RNase inhibitor. Each sample was separated on a 0.6% agarose
gel containing 0.5 Tris-borate-EDTA (TBE) buffer.
GST pulldown assay. GST-Prp18 and GST were incubated with either NP, vRNP, or micrococcal
nuclease-treated vRNP (mnRNP) at 25°C for 1 h in a buffer containing 50 mM HEPES-NaOH (pH 8.0), 20
mM KCl, 1.2 mM MgCl2, 0.6 mM dithiothreitol, 0.1% Triton X-100, 4 U of the RNase inhibitor, and
glutathione-Sepharose 4B beads. After washing with a buffer containing 20 mM Tris-HCl (pH 8.0), 200
mM NaCl, 1 mM EDTA, and 0.1% Triton X-100, proteins bound to the beads were eluted and analyzed
by immunoblotting with anti-His and anti-GST antibodies.
RNase digestion assay. A cell-free viral RNA synthesis reaction was performed as described above.
After incubation for 4 min at 30°C, the reaction was stopped by the addition of 50 mM EDTA, and the
mixture was then further incubated with RNase T2 at 30°C for 5 min. RNA was puriﬁed by phenol-
chloroform extraction and ethanol precipitation and analyzed on 8 M urea–4% PAGE gels.
Gene knockdown experiments. HeLa cells (2  105 cells) were transfected with 50 pmol of Stealth
RNAi (catalog number PRPF-HSS112527; Life Technologies) using the Lipofectamine RNAiMAX transfec-
tion reagent (Life Technologies) according to the manufacturer’s protocols.
Quantitative RT-PCR. Total RNA was prepared by the acid guanidinium phenol chloroform (AGPC)
method and then reverse transcribed with the following primers: 5=-GAGAGAGGAGAAGAGACA-3= for
segment 3 vRNA, 5=-AGTAGAAACAAGGTACTTTTTTGGAC-3= for segment 3 cRNA, 5=-GACGATGCAACGG
CTGGTCTG-3= for segment 5 vRNA, 5=-AGTAGAAACAAGGGTATTTTTCTTTA-3= for segment 5 cRNA, 5=-G
TCGAAACGTACGTTCTCTCTATC-3= for segment 7 vRNA, 5=-AGTAGAAACAAGGTAGTTTTTTACTC-3= for seg-
ment 7 cRNA, oligo(dT)20 for viral mRNA, and 5=-GGTGTGTTACAAAGGGCAGGG-3= for 18S rRNA. Single-
stranded cDNAs were then subjected to quantitative real-time PCR with following speciﬁc primer sets:
5=-GAGAGAGGAGAAGAGACA-3= and 5=-TTAATTTTAAGGCATCCATCAGCAGG-3= for segment 3, 5=-AGCA
TTGTTCCAACTCCTTT-3= and 5=-GACGATGCAACGGCTGGTCTG-3= for segment 5, 5=-GTCGAAACGTACGTT
CTCTCTATC-3= and 5=-TCCCCTTAGTCAGAGGTGAC-3= for segment 7 and M1 mRNA, 5=-GAGGTCGAAAC
GCCTAT-3= and 5=-CTCCAGCTCTATGTTGACAAA-3= for M2 mRNA, and 5=-AACGGCTACCACATCCAAGG-3
and 5=-GGGAGTGGGTAATTTGCGC-3= for 18S rRNA, respectively.
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